|
The
company reported adjusted revenue of $6.78 billion in the fourth
quarter ended Dec. 31, below analysts' average estimate of $6.91
billion, according to Thomson Reuters I/B/E/S/.
Sales of its cancer drug Imbruvica, which is also marketed by
Johnson & Johnson, and its hepatitis C treatment Vikiera Pak
fell short of consensus estimates, according to Evercore ISI.
Sales of Humira, the company's arthritis treatment, rose 15.5
percent to $4.29 billion in the latest quarter, just ahead of
the consensus estimate of $4.26 billion, according to Evercore
ISI.
Humira, the world's biggest-selling drug, is also used to treat
Crohn's disease and psoriasis.
The company said on Friday net profit fell to $1.39 billion, or
85 cents per share, in the fourth quarter ended Dec. 31, from
$1.52 billion, or 92 cents per share, a year earlier.
Excluding special items, the suburban Chicago drugmaker earned
$1.20 per share, in line with the average analyst estimate.
Net revenue rose to $6.80 billion from $6.40 billion.
AbbVie said it expected 2017 adjusted earnings of $5.44 to $5.54
per share, compared with analysts' estimate of $5.47.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by
Sriraj Kalluvila)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
